🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Tomas, Nadia, Hannes Ausserwöger, Kadi-Liis Saar, Tim Welsh , Daoyuan Qian, Georg Krainer and Alex Borodavka on publishing their work on the antimicrobial peptide mechanisms of action through LLPS! nature.com/articles/s4146…

👇We are hiring! Prof in #Synthetic Biology or #Bioengineering

Excited to announce my election to the Estonian Young Academy of Sciences. I am grateful for the recognition and committed to continue advancing science and education globally. Fantastic to see Academy proactively including scientists working abroad. akadeemia.ee/eesti-noorte-t…

The first Practical Cheminformatics post of the year is a retrospective of papers published in 2023, “AI in Drug Discovery 2023 - A Highly Opinionated Literature Review”. practicalcheminformatics.blogspot.com/2024/01/ai-in-…

Estonian-founded delivery company Starship raises USD90 million estonianworld.com/business/eston… via @estonianworld #Starship #Estonia #startups #robots

Great overview of challenges on which ML/comp methods should focus (and thankfully already to some degree do) to help accelerate progress in drug discovery. cell.com/cell/fulltext/…

In-depth perspective on the first CACHE challenge in Nature Reviews Drug Discovery nature.com/articles/d4157… #compchem Structural Genomics Consortium (SGC) Conscience

Great peak into state-of-the-art foundational models for biology. A single model predicting the fitness of RNA and proteins with extension to gene essentiality and CRISPR system generation. Beautifully executed by Arc Institute. How many months until we see this for eukaryotes?🙂

Our review on diffusion models for protein structures and docking is out Hannes Stärk Gabriele Corso Bowen Jing Regina Barzilay Tommi Jaakkola. This summarize the advancements up to 2023. There have been lots of exciting new works since! wires.onlinelibrary.wiley.com/doi/10.1002/wc…

Head taasiseseisvumispäeva! 🇬🇧🇪🇪

For all its flaws, I would argue the biotech industry is still *the* single best place to work today with a tech background 1- Intellectually, you get to work on some of the hardest problems of our time and they won’t be solved anytime soon. 2- The field is undergoing a

What a crazy 4 months it has been! Today we announced that Recursion & Exscientia shareholders have overwhelmingly approved the proposed business combination! Behind the scenes, our teams have been hard at work planning for a successful close and then to continue

Here’s an alternative, more accurate title: “Recursion grows from ~550 to ~800 employees with close of Exscientia merger.” …but probably doesn’t get as many clicks as the negative ones that seem so in vogue these days…

Very excited - another first patient dosed in an area of high unmet need. The flywheel is really beginning to roll…

💙Population 1,3 million, total area 45 228 km2 🖤Almost 50% covered by 🌲 🤍The most startups per capita in Europe. 💙One of the least religious countries in the world. 🖤Third tallest people on Earth. 🤍Highest number of supermodels per capita. 💙World's 5th toughest language

We just announced our Q4 and FY2024 financial results. It has been a momentous year for Recursion and the TechBio industry, with a number of critical factors now converging to allow us to rapidly accelerate our efforts to transform drug discovery and development. Across

An excellent first day in Estonia, experiencing the warmth and hospitality of this beautiful country 🇪🇪

Today we announced that the first patient has been dosed in our Phase 1 trial of REC-3565 – a potential best-in-class MALT1 inhibitor for the treatment of relapsed or refractory B-cell lymphomas which impacts approximately 41,000 patients in the U.S. and EU5. 🔹 On REC-3565